NCT00336453View on ClinicalTrials.gov

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Vaccination

0.5mL dose for intramuscular injection

BIOLOGICAL

Influenza Vaccination

0.25mL dose for intramuscular injection

Trial Locations (3)

15241

Primary Physicians Research, Pittsburgh

40004

Kentucky pediatric /Adult Research, Bardstown

63110

Saint Louis University, St Louis

All Listed Sponsors
lead

Protein Sciences Corporation

INDUSTRY

NCT00336453 - Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics | Biotech Hunter | Biotech Hunter